Terms: = Kidney tumors AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Treatment
3034 results:
1. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
[TBL] [Abstract] [Full Text] [Related]
2. SCPLPA: An miRNA-disease association prediction model based on spatial consistency projection and label propagation algorithm.
Chen M; Deng Y; Li Z; Ye Y; Zeng L; He Z; Peng G
J Cell Mol Med; 2024 May; 28(9):e18345. PubMed ID: 38693850
[TBL] [Abstract] [Full Text] [Related]
3. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract] [Full Text] [Related]
4. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
Wolf MM; Madden MZ; Arner EN; Bader JE; Ye X; Vlach L; Tigue ML; Landis MD; Jonker PB; Hatem Z; Steiner KK; Gaines DK; Reinfeld BI; Hathaway ES; Xin F; Tantawy MN; Haake SM; Jonasch E; Muir A; Weiss VL; Beckermann KE; Rathmell WK; Rathmell JC
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618956
[TBL] [Abstract] [Full Text] [Related]
5. Pazopanib stimulates senescence of renal carcinoma cells through targeting nuclear factor E2-related factor 2 (Nrf2).
Wang X; Yang J; Li D; Teng L; Chen Y; Meng J; Yang C; Yin Z; Li C
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23689. PubMed ID: 38613465
[TBL] [Abstract] [Full Text] [Related]
6. The application strategy of liposomes in organ targeting therapy.
Xun Z; Li T; Xue X
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1955. PubMed ID: 38613219
[TBL] [Abstract] [Full Text] [Related]
7. Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis.
Wang Y; Chen X; Tang N; Guo M; Ai D
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612943
[TBL] [Abstract] [Full Text] [Related]
8. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract] [Full Text] [Related]
9. Safety of Docetaxel in a Patient with Metastatic Castration-Resistant Prostate Cancer After kidney Transplantation: A Case Report.
Nagahisa C; Iizuka J; Kobari Y; Minoda R; Oki R; Unagami K; Yoshida K; Hirai T; Omoto K; Shimizu T; Ishida H; Takagi T
Transplant Proc; 2024 Apr; 56(3):729-733. PubMed ID: 38548511
[TBL] [Abstract] [Full Text] [Related]
10. The influence of microwave ablation parameters on the positioning of trocar in different cancerous tissues: a numerical study.
Satish V; Repaka R
Electromagn Biol Med; 2024 Apr; 43(1-2):125-134. PubMed ID: 38533761
[TBL] [Abstract] [Full Text] [Related]
11. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C; Jacquel A; Pandiani C; Rastoin O; Dawaliby R; Schmitt T; Bourgoin M; Palenzuela H; Rossi AL; Ambrosetti D; Durivault J; Luciano F; Borchiellini D; Le Du J; Gonçalves LCP; Auberger P; Benhida R; Kinget L; Beuselinck B; Ronco C; Pagès G; Dufies M
J Exp Clin Cancer Res; 2024 Mar; 43(1):86. PubMed ID: 38504270
[TBL] [Abstract] [Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases.
Qian L; Zhu Y; Deng C; Liang Z; Chen J; Chen Y; Wang X; Liu Y; Tian Y; Yang Y
Signal Transduct Target Ther; 2024 Mar; 9(1):50. PubMed ID: 38424050
[TBL] [Abstract] [Full Text] [Related]
13. Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and Prostate Cancer.
Mizutani K; Sugiyama S; Kameyama K; Kamei S; Yokoi S; Morikawa A; Takeuchi M; Seike K; Yamada T; Ehara H; Sawada S; Hirade K; Furuta H; Matsunaga K; Yamada T; Sakamoto I; Kato Y; Nishihara H; Ishihara S; Deguchi T
Cancer Genomics Proteomics; 2024; 21(2):203-212. PubMed ID: 38423595
[TBL] [Abstract] [Full Text] [Related]
14. The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Sato H; Ito T; Hayashi T; Kitano S; Erdjument-Bromage H; Bott MJ; Toyooka S; Zauderer M; Ladanyi M
Oncogene; 2024 Apr; 43(15):1087-1097. PubMed ID: 38383726
[TBL] [Abstract] [Full Text] [Related]
15. VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
[TBL] [Abstract] [Full Text] [Related]
16. Big data analytics for MerTK genomics reveals its double-edged sword functions in human diseases.
Liu S; Wu J; Yang D; Xu J; Shi H; Xue B; Ding Z
Redox Biol; 2024 Apr; 70():103061. PubMed ID: 38341954
[TBL] [Abstract] [Full Text] [Related]
17. Correlations of SDF-1ɑ and XRCC1 gene polymorphisms with the risk of renal cancer development and bioinformatics studies of SDF-1α and XRCC1 and the prognosis of renal cancer.
Zhang W; Su Y; Yue G; Zhao L; Li H; Jia M; Wang Y; Liu D; Wang H; Gao Y
Sci Rep; 2024 Feb; 14(1):3367. PubMed ID: 38337001
[TBL] [Abstract] [Full Text] [Related]
18. Identification of Erzhu Jiedu Recipe and its molecular mechanism underlying inhibited human hepatoma cells by UHPLC-Q-Exactive Orbitrap HRMS and network pharmacology.
Wang F; Mai J; Wang H; Xu Y; Zhou X; Xie Z; Yu B; Liu P; Liu W; Cheng Y
J Ethnopharmacol; 2024 May; 325():117893. PubMed ID: 38336184
[TBL] [Abstract] [Full Text] [Related]
19. Disulfideptosis-associated lncRNAs reveal features of prognostic, immune escape, tumor mutation, and tumor malignant progression in renal clear cell carcinoma.
Li X; Deng X; Liu T; Zhang W; Tao J
Aging (Albany NY); 2024 Feb; 16(4):3280-3301. PubMed ID: 38334964
[TBL] [Abstract] [Full Text] [Related]
20. Immune Modulation with RANKL Blockade through Denosumab treatment in Patients with Cancer.
Chang H; Marquez J; Chen BK; Kim DM; Cheng ML; Liu EV; Yang H; Zhang L; Sinha M; Cheung A; Kwek SS; Chow ED; Bridge M; Aggarwal RR; Friedlander TW; Small EJ; Anderson M; Fong L
Cancer Immunol Res; 2024 Apr; 12(4):453-461. PubMed ID: 38276989
[TBL] [Abstract] [Full Text] [Related]
[Next]
